Project Grant K01HL186353
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals $3,302,181 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to assess heart failure risk factors and prediction models in people with HIV through a cohort study in three integrated health systems. The research will compare the impact of traditional and HIV-specific risk factors on incident heart failure among people with HIV and demographically matched people without HIV; evaluate...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Kaiser Foundation Hospitals $3.92 million through the Cardiovascular Diseases Research program (CFDA 93.837) on September 27, 2025, for the HIDDEN-ASCVD (Harnessing Artificial Intelligence and Deep Learning to Determine a Coronary Artery Calcium Estimate in Patients with No History of Atherosclerotic Cardiovascular Disease) Study, with completion scheduled for August 31, 2029. The project leverages deep...
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals $193,055 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support Dr. Vy Ho's transition to an independent surgeon-informaticist specializing in abdominal aortic aneurysm diagnosis, surveillance, and treatment. The award funds formal training in computer vision for cardiovascular risk prediction, risk factors for abdominal aortic aneurysms in underrepresented patient...
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals $1.758 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a cohort study characterizing postmenopausal androgens, sex hormone binding globulin, and their association with cardiovascular risk in older women. The research leverages an ancillary study to the Women's Health Initiative, utilizing stored biospecimens and cardiovascular risk markers collected across two...
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals' Kaiser Foundation Research Institute $1,470,439 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate optimal physical activity timing and 24-hour activity composition for prevention of hypertensive disorders of pregnancy. The research addresses gaps in understanding how the timing and intensity of physical activity during pregnancy—particularly early versus...
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals $780,960 on July 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate treatment adherence interventions for young adults with obstructive sleep apnea. The award funds a five-year randomized controlled trial testing two interventions designed to improve continuous positive airway pressure (CPAP) treatment adherence among young adults ages 18–25. The research addresses a documented...
- The Food and Drug Administration awarded Kaiser Foundation Hospitals a cooperative agreement totaling $2,996,928 on September 22, 2025, under the Food and Drug Administration Research program (CFDA 93.103). The award funds development of artificial intelligence-enabled echocardiographic biomarkers and real-world electronic health record data models to improve early detection and risk stratification of cancer therapy-related cardiac dysfunction (CTRCD) in cancer survivors. The recipient will...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Kaiser Foundation Hospitals $663,216 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to conduct a five-year study examining bone and muscle properties associated with fracture risk among persons living with HIV infection. The research leverages the Kaiser Permanente Southern California HIV Registry and electronic health records to compare bone, muscle, and body...
- The National Institute on Aging awarded Kaiser Foundation Hospitals $2.495 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to investigate missed home health care in older adults with Alzheimer's disease and related dementias. The project, titled "Missed Home Health Care in Older Adults with Dementia: Identifying Drivers, Outcomes, and Costs," uses mixed methods to identify correlates and drivers of missed home health care following hospital discharge,...
- The National Cancer Institute awarded Kaiser Foundation Hospitals $440,440 on August 1, 2026, to develop a statistical framework for predicting surveillance mammography failure in breast cancer survivors under the Cancer Cause and Prevention Research program (CFDA 93.393). The project addresses the clinical challenge that surveillance mammography in breast cancer survivors detects only 70.4 percent of recurrences, missing nearly 30 percent of second breast cancers. Kaiser will build a risk...
The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals $200,832 on August 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing project grant K01HL186353) to support a five-year research training and development initiative focused on cardiovascular disease prevention in Spanish-speaking families. The award funds Dr. Formagini's research to adapt an existing text-messaging lifestyle change program—originally developed for Spanish-speaking adults—to target family member dyads and evaluate its feasibility, acceptability, and preliminary effects within Kaiser Permanente Southern California. The project aims to improve accessibility and impact of evidence-based lifestyle interventions, which have demonstrated that modest body weight loss through physical activity and dietary changes leads to improved cardiovascular health, particularly for populations where obesity and diabetes are highly prevalent. Specific Aim 1 involves adapting a six-month text-messaging library for Spanish-speaking family dyads in collaboration with an expert advisory board, with messages tailored to promote joint lifestyle change. Kaiser Foundation Research Institute, operating as Kaiser Permanente and based in Pasadena, California, serves as the prime recipient. The award period runs from August 12, 2026, through July 31, 2031. The project is classified as a K01 research training grant, designed to provide Dr. Formagini with training and experience to establish her as an independent investigator in cardiovascular disease prevention.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $200.8k | 8/13/26 |